Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (SUNBEAM): a multicentre, randomised, minimum 12-month, phase 3 trial
Jazyk angličtina Země Velká Británie, Anglie Médium print-electronic
Typ dokumentu klinické zkoušky, fáze III, srovnávací studie, časopisecké články, multicentrická studie, randomizované kontrolované studie, práce podpořená grantem
PubMed
31492651
DOI
10.1016/s1474-4422(19)30239-x
PII: S1474-4422(19)30239-X
Knihovny.cz E-zdroje
- MeSH
- atrioventrikulární blokáda chemicky indukované MeSH
- bradykardie chemicky indukované MeSH
- dospělí MeSH
- imunosupresiva škodlivé účinky terapeutické užití MeSH
- indany škodlivé účinky terapeutické užití MeSH
- interferon beta 1a škodlivé účinky terapeutické užití MeSH
- kognitivní poruchy etiologie MeSH
- kvalita života MeSH
- lidé středního věku MeSH
- lidé MeSH
- magnetická rezonanční tomografie MeSH
- mozek patologie MeSH
- neurozobrazování MeSH
- oxadiazoly škodlivé účinky terapeutické užití MeSH
- progrese nemoci MeSH
- receptory sfingosin-1-fosfátu antagonisté a inhibitory MeSH
- relabující-remitující roztroušená skleróza farmakoterapie patologie psychologie MeSH
- šedá hmota patologie MeSH
- stupeň závažnosti nemoci MeSH
- velikost orgánu MeSH
- Check Tag
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- klinické zkoušky, fáze III MeSH
- multicentrická studie MeSH
- práce podpořená grantem MeSH
- randomizované kontrolované studie MeSH
- srovnávací studie MeSH
- Názvy látek
- imunosupresiva MeSH
- indany MeSH
- interferon beta 1a MeSH
- oxadiazoly MeSH
- ozanimod MeSH Prohlížeč
- receptory sfingosin-1-fosfátu MeSH
BACKGROUND: Ozanimod, a sphingosine 1-phosphate receptor modulator, selectively binds to receptor subtypes 1 and 5 with high affinity. The RADIANCE phase 2 study showed that ozanimod had better efficacy than placebo on MRI measures, with a favourable safety profile, in participants with relapsing multiple sclerosis. The SUNBEAM study aimed to assess the safety and efficacy of ozanimod versus intramuscular interferon beta-1a in participants with relapsing multiple sclerosis. METHODS: SUNBEAM was a randomised, double-blind, double-dummy, active-controlled phase 3 trial done at 152 academic medical centres and clinical practices in 20 countries. We enrolled participants aged 18-55 years with relapsing multiple sclerosis, baseline expanded disability status scale (EDSS) score of 0·0-5·0, and either at least one relapse within the 12 months before screening or at least one relapse within 24 months plus at least one gadolinium-enhancing lesion within 12 months before screening. Participants were randomly assigned 1:1:1 by a blocked algorithm stratified by country and baseline EDSS score to at least 12 months treatment of either once-daily oral ozanimod 1·0 mg or 0·5 mg or weekly intramuscular interferon beta-1a 30 μg. Participants, investigators, and study staff were masked to treatment assignment. The primary endpoint was annualised relapse rate (ARR) during the treatment period and was assessed in the intention-to-treat population. Safety was assessed in all participants according to the highest dose of ozanimod received. This trial is registered at ClinicalTrials.gov, number NCT02294058 and EudraCT, number 2014-002320-27. FINDINGS: Between Dec 18, 2014, and Nov 12, 2015, 1346 participants were enrolled and randomly assigned to ozanimod 1·0 mg (n=447), ozanimod 0·5 mg (n=451), or interferon beta-1a (n=448). 91 (6·8%) participants discontinued the study drug (29 in the ozanimod 1·0 mg group; 26 in the ozanimod 0·5 mg group; and 36 in the interferon beta-1a group). Adjusted ARRs were 0·35 (0·28-0·44) for interferon beta-1a, 0·18 (95% CI 0·14-0·24) for ozanimod 1·0 mg (rate ratio [RR] of 0·52 [0·41-0·66] vs interferon beta-1a; p<0·0001), and 0·24 (0·19-0·31) for ozanimod 0·5 mg (RR 0·69 [0·55-0·86] vs interferon beta-1a; p=0·0013). Few ozanimod-treated participants discontinued treatment because of adverse events (13 [2·9%] who received ozanimod 1·0 mg; seven [1·5%] who received ozanimod 0·5 mg; and 16 [3·6%] who received interferon beta-1a). No first-dose, clinically significant bradycardia or second-degree or third-degree atrioventricular block was reported. The incidence of serious adverse events was low and similar across treatment groups (13 [2·9%] participants who received ozanimod 1·0 mg; 16 [3·5%] who received ozanimod 0·5 mg; and 11 [2·5%] who received interferon beta-1a). No serious opportunistic infections occurred in ozanimod-treated participants. INTERPRETATION: In participants with relapsing multiple sclerosis treated for at least 12 months, ozanimod was well tolerated and demonstrated a significantly lower relapse rate than interferon beta-1a. These findings provide support for ozanimod as an oral therapy for individuals with relapsing multiple sclerosis. FUNDING: Celgene International II.
Department of Biostatistics Celgene Corporation Summit NJ USA
Department of Clinical Development Celgene Corporation Summit NJ USA
Department of Neurology Medical Faculty Heinrich Heine University Dusseldorf Germany
Drug Safety Celgene Corporation Summit NJ USA
Mellen Center for Multiple Sclerosis Treatment and Research Cleveland Clinic Cleveland OH USA
Neurologic Clinic and Policlinic University Hospital and University of Basel Basel Switzerland
NeuroRx Research and Montreal Neurological Institute McGill University Montreal QC Canada
Citace poskytuje Crossref.org
Managing multiple sclerosis in individuals aged 55 and above: a comprehensive review
Bioavailable central nervous system disease-modifying therapies for multiple sclerosis
ClinicalTrials.gov
NCT02294058